Canaccord Genuity Maintains Buy on Eton Pharmaceuticals, Raises Price Target to $80
Benzinga Newsdesk 7 hours ago
Analyst RatingsNewsPrice Target
Canaccord Genuity analyst Gary Nachman maintains Eton Pharmaceuticals (NASDAQ:ETON) with a Buy and raises the price target from $68 to $80.
Canaccord Genuity analyst Gary Nachman maintains Eton Pharmaceuticals (NASDAQ:ETON) with a Buy and raises the price target from $68 to $80.